Memry — Noble Investor Conference 2006
25 slides from Memry's conference presentation, Sep 26, 2006

Slide 1: Noble Investor Conference September 26, 2006
Noble Investor Conference September 26, 2006 Exhibit 99.1

Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements which involve known and unknown risks, uncertainties or other factors not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, perfo

Slide 3: Mission Statement
Mission Statement “Enabling minimally invasive and targeted therapies for the medical industry”

Slide 4: Memry Today
Memry Today A Medical product outsourcer of innovative, custom solutions Our Technologies Fully integrated producer of nitinol tubing and wire, components and subassemblies Largest independent producer of laser cut & finished nitinol stents & structures High-end polymer extrusions Our Markets 95% me

Slide 5: A Growing Company In A Growing Medical Device Market
A Growing Company In A Growing Medical Device Market (Source: Millennium Research Group, October 2005) $58.5B $97.3B Major Segments 2009 2004 Orthopaedics Surgery/endosurgery Cardiovascular $30.3 $32.7 $34.3 $21.3 $19.3 $17.9

Slide 6: Non- and Minimally Invasive U.S. Device Market
Non- and Minimally Invasive U.S. Device Market (Source: BCC Research, June 2006) $7.2B $11.0B $1.3 $1.6 $8.1 $5.1 $1.3 $0.8 2011 2005 Orthopaedics Surgery/endosurgery Cardiovascular Monitoring/imaging Electrosurgical/auxiliary equipment Robotics Surgical devices & instruments 78.3% 11.3% 7.9% 2.5% $

Slide 7: Medical Device Industry Undergoing Rapid Change
Medical Device Industry Undergoing Rapid Change * Millennium Research Group, October 2005 Vendor base consolidation Cost containment Aging population Mergers & acquisitions Globalization Stringent regulatory environment Innovation & technology Improving quality of healthcare Speed to market External

Slide 8: Medical Device Outsourcing Market By Segment & Capability
Medical Device Outsourcing Market By Segment & Capability (Source: Millennium Research Group, October 2005) Orthopaedics Surgery/endosurgery Cardiovascular Design engineering Packaging & warehouse Sterilization Final assembly Component manufacturing $4.0B $7.7B 2009 2004 20.2% 15.6% 44.7% 8.6% 10.9%

Slide 9: Success Factors For the Outsourcing Industry
Success Factors For the Outsourcing Industry Quality & competitive pricing Management of convergence of key technologies Full service capabilities including combination products Device application knowledge Globalization Supply chain management Rapid turnaround Success

Slide 10: Value Implications for Outsourcers
Value Implications for Outsourcers $$$ Where a company is on value chain is extremely important to long-term viability of business and value places on it Simply providing materials or single component to an end product no longer enough Leveraging and combining core materials and processing expertise

Slide 11: Subcontractors
Subcontractors - Serni-finished material Customer < Final Assembly € Micro-machining 1 ————————— Micro-machining 2 Component Finishing

Slide 12: Shape Memory Alloy Technology
Shape Memory Alloy Technology A Unique Material with Enabling Properties Minimally invasive & endovascular devices Materials & Processes Superelastic & shape memory nitinol alloys Wire & tube drawing Laser cutting Stent manufacturing Wire forming Surface finishing Grinding & coating Assembly Enablin

Slide 13: Polymer Extrusion Technology
Polymer Extrusion Technology A Strategic Process Technology Catheter-based minimally invasive & endovascular devices Materials & Processes Custom co-extended polymer components Polyurethanes Nylons Polyesters Flouropolymers Polyimides Tipping & forming Tapering Grinding Braiding & coiling Enabling P

Slide 14: Memry FY 2006 By Specialty & Application
Memry FY 2006 By Specialty & Application Embolic protection Catheters Guidewires Endosurgical instruments Stents & stent grafts 19% Vascular/radiology Urology/OBGYN Neurology Coronary & EP Endosurgery Orthopaedics 1% 62% 18% 3% 5% 11% 34% 20% 24% 3% 19% 1% 62% 18% 3% 5% 11% 34% 20% 24% 3%

Slide 15: Memry & Putnam A Better Team
Memry & Putnam A Better Team Strong leverage of respective customer and application bases Ability to build on knowledge base of metals and polymers in new ways to provide innovative and unique solutions to customers Enlarging targeted markets Providing increasing levels of expertise in minimally inv

Slide 16: Memry + Putnam Creating Synergies
Memry + Putnam Jacketed Guidewire Biomer Technology Stent Coating Memry Stent Putnam Extruded Catheter Tubing Creating Synergies

Slide 17: Business Development Objectives
Business Development Objectives Market leadership & recognition as leading provider of technology and synergistic solutions for minimally invasive & targeted therapy products High-end processing technologies Passive and biointeractive medical polymers & biomaterials Surface modification & finishing

Slide 18: Management Team
Management Team Robert Belcher Chief Executive Officer Dean Tulumaris President and Chief Operating Officer Richard Sowerby Chief Financial Officer and Treasurer James Dandeneau President Putnam Plastics Division Philippe Poncet Vice President Business Development

Slide 19: Revenue Growth
Revenue Growth (in millions) Fiscal Year $26.9 $29.9 $32.9 $34.0 $34.5 $45.0 $52.6 2000 2001 2002 2003 2004 2005 2006 $26.9 $29.9 $32.9 $34.0 $34.5 $45.0 $52.6 2000 2001 2002 2003 2004 2005 2006

Slide 20: Income Statement
Income Statement FY 2006 FY 2005 FY 2004 Revenues $52.6M $45.0M $34.5M Gross Profit $20.4M $17.9M $13.8M Gross Margin 39% 40% 40% Net Income $2.7M* $2.7M** $2.4M Diluted EPS $0.09 $0.10 $0.09 * Includes ($1.1M) of CEO retirement charges, net of $0.4M tax provision **Includes ($0.2M) on extinguishmen

Slide 21: Balance Sheet
Balance Sheet (in millions) $ 1.5 $ 11.4 $ 10.0 Total Debt - - 0.1 Non-current Liabilities $ 33.0 $ 52.8 $ 55.3 Total Liabilities and Stockholders’ Equity 28.2 35.8 39.5 Stockholders’ Equity 1.2 8.7 7.8 Notes Payable, less current maturities $ 3.6 $ 8.3 $ 7.9 Current Liabilities $33.0 $52.8 $ 55.3 T

Slide 22: EBITDA & Adjusted Definition
EBITDA & Adjusted Definition In this presentation, the Company refers to EBITDA and Adjusted EBITDA, financial measures that are not recognized under accounting principles generally accepted in the United States of America (“GAAP”). The Company defines EBITDA as earnings before income taxes, interes

Slide 23: EBITDA
EBITDA (in millions) 15.1% 18.2% 18.4% Adjusted EBITDA % - 0.2 - + Early Extinguishment of Debt (c) $ 5.2 $ 8.2 $ 9.7 Adjusted EBITDA 0.1 0.1 0.4 + Equity Based Compensation (d) - - 1.1 + CEO Retirement (b) $ 5.1 $ 7.9 $ 8.2 EBITDA 0.2 0.6 0.7 + Amortization (a) 1.7 1.9 2.1 + Depreciation - 1.0 1.1

Slide 24: Footnotes to EBITDA
Footnotes to EBITDA a) Amortization excludes the amortization of deferred financing costs, which is included in interest expense, net. b) Effective December 9, 2005, the Company’s President and Chief Executive Officer retired from his position. In connection with the retirement, the Company recorded

Slide 25: Investor Summary
Investor Summary Provides innovative and strategic technology solutions to the medical device industry Materials and process technologies Nitinol and Shape Memory Alloys Highly customized polymer extrusions Customers include world’s largest device companies and emerging start-ups New applications an
Source: SEC EDGAR · 8-K filed Sep 26, 2006


